Core Viewpoint - Tempus AI, Inc. has announced a strategic collaboration with Blood Cancer United to develop a patient-centered registry for pediatric acute myeloid leukemia, aiming to enhance precision medicine in this area [1] Company Summary - Tempus AI, Inc. is a technology company focused on advancing precision medicine through the adoption of artificial intelligence [1] - Blood Cancer United, formerly known as The Leukemia & Lymphoma Society, is the largest global nonprofit dedicated to supporting blood cancer patients, conducting research, and advocating for the community [1] Industry Summary - The collaboration targets pediatric acute myeloid leukemia (pAML), which is identified as a rare and aggressive form of blood cancer [1]